Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

PURPOSE: The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide–paclitaxel regimen. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaz-Luis, Ines, Barroso-Sousa, Romualdo, Di Meglio, Antonio, Hu, Jiani, Rees, Rebecca, Sinclair, Natalie, Milisits, Lindsey, Leone, Jose Pablo, Constantine, Michael, Faggen, Meredith, Briccetti, Frederick, Block, Caroline, O'Neil, Kelly, Partridge, Ann, Burstein, Harold, Waks, Adrienne G., Trippa, Lorenzo, Tolaney, Sara M., Hassett, Michael, Winer, Eric P., Lin, Nancy U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367545/
https://www.ncbi.nlm.nih.gov/pubmed/32330102
http://dx.doi.org/10.1200/JCO.19.02484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367545/
https://www.ncbi.nlm.nih.gov/pubmed/32330102
http://dx.doi.org/10.1200/JCO.19.02484

Ejemplares similares